Alternatively, the sialic acids on the tumor may be enzymatically removed by targeting tumor cells using tumor‐specific antibodies (anti‐HER2) coupled to a sialidase, which subsequently cleaves the sialic acids, thereby releasing the brakes on the immune system [207]. Here, ERBB2 is linked to neoplasm.